CF

Conformis IncNASDAQ CFMS Stock Report

Last reporting period 30 Jun, 2023

Updated —

Last price

Market cap $B

0.018

Micro

Exchange

XNAS - Nasdaq

CFMS Stock Analysis

CF

Uncovered

Conformis Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-34/100

Low score

Market cap $B

0.018

Dividend yield

Shares outstanding

7.496 B

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 295 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's unique knee and hip anatomy. The Company’s products include iUni, iDuo, iTotal CR, iTotal PS, iTotal Identity, Identity Imprint and Conformis Cordera hip system. The Company’s iFit Image-to-Implant technology platform includes iFit Design, iFit Printing and iFit Just-in-Time Delivery. Its Identity Imprint knee system provides a data-informed knee implant system that provides a level of personalization through its patient-specific instruments (PSI) and proprietary algorithms for pre-surgical planning. Its Image-to-Implant Platinum Services program offering services in United States. The firm offers a line of the sterile, personalized knee and hip implants and single-use instruments delivered to hospitals.

View Section: Eyestock Rating